The pharmaceutical community is intrigued by retatrutide, a new dual GIP and GLP-1 target that’s showing impressive results in early research. This compound works by mimicking natural hormones to regulate appetite and increase feelings of satisfaction , ultimately resulting in considerable body decrease. While presently under review and not broad